Phase 1Completed
Haplo Peripheral Blood Sct In GVHD Prevention
Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study
- Sponsor
- Zachariah Michael DeFilipp (Academic or other)
- Enrollment
- 25 enrolled
- Conditions
- GVHD; AML; ALL; MDS; MPN; CMML; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Blood Stem Cell Transplant Failure; Graft Vs Host Disease; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia
- Interventions
- FLUDARABINE; CYCLOPHOSPHAMIDE; TBI; Melphalan; Sirolimus; Mycophenolate mofetil; RGI-2001; CYCLOPHOSPHAMIDE
- Ages
- adults, older adults
- Registry
- NCT04473911
Full record on ClinicalTrials.gov
From the registry
This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation. * GVHD is a condition in which cells from the donor's tissue attack the organs. * RGI-2001 is an investigational treatment
Primary outcomes
- Number of patients achieving successful donor engraftment
History
Last registry update
Study completion
Primary completion
Started
Registered